Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment

Background: Diabetes mellitus is a complicated disease with a pathophysiology that includes hyperinsulinemia, hyperglycemia and other metabolic impairments leading to many clinical complications. It is necessary to develop appropriate treatments to manage the disease and reduce possible acute and ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Rasouli, Mina, Ahmad, Zalinah, Omar, Abdul Rahman, Allaudin, Zeenathul Nazariah
Format: Article
Language:English
Published: BioMed Central 2011
Online Access:http://psasir.upm.edu.my/id/eprint/24523/1/24523.pdf
http://psasir.upm.edu.my/id/eprint/24523/
https://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-11-99
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Putra Malaysia
Language: English
id my.upm.eprints.24523
record_format eprints
spelling my.upm.eprints.245232019-10-30T06:22:38Z http://psasir.upm.edu.my/id/eprint/24523/ Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment Rasouli, Mina Ahmad, Zalinah Omar, Abdul Rahman Allaudin, Zeenathul Nazariah Background: Diabetes mellitus is a complicated disease with a pathophysiology that includes hyperinsulinemia, hyperglycemia and other metabolic impairments leading to many clinical complications. It is necessary to develop appropriate treatments to manage the disease and reduce possible acute and chronic side effects. The advent of gene therapy has generated excitement in the medical world for the possible application of gene therapy in the treatment of diabetes. The glucagon-like peptide-1 (GLP-1) promoter, which is recognised by gut L-cells, is an appealing candidate for gene therapy purposes. The specific properties of L-cells suggest that L-cells and the GLP-1 promoter would be useful for diabetes therapy approaches. Results: In this study, L-cells were isolated from a primary intestinal cell line to create suitable target cells for insulin expression studies. The isolated cells displayed L-cell properties and were therefore used as an L-cell surrogate. Next, the isolated L-cells were transfected with the recombinant plasmid consisting of an insulin gene located downstream of the GLP-1 promoter. The secretion tests revealed that an increase in glucose concentration from 5 mM to 25 mM induced insulin gene expression in the L-cells by 2.7-fold. Furthermore, L-cells quickly responded to the glucose stimulation; the amount of insulin protein increased 2-fold in the first 30 minutes and then reached a plateau after 90 minutes. Conclusion: Our data showed that L-cells efficiently produced the mature insulin protein. In addition, the insulin protein secretion was positively regulated with glucose induction. In conclusion, GLP-1 promoter and L-cell could be potential candidates for diabetes gene therapy agents. BioMed Central 2011 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/24523/1/24523.pdf Rasouli, Mina and Ahmad, Zalinah and Omar, Abdul Rahman and Allaudin, Zeenathul Nazariah (2011) Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment. BMC Biotechnology, 11. art. no. 99. pp. 1-8. ISSN 1472-6750 https://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-11-99 10.1186/1472-6750-11-99
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Background: Diabetes mellitus is a complicated disease with a pathophysiology that includes hyperinsulinemia, hyperglycemia and other metabolic impairments leading to many clinical complications. It is necessary to develop appropriate treatments to manage the disease and reduce possible acute and chronic side effects. The advent of gene therapy has generated excitement in the medical world for the possible application of gene therapy in the treatment of diabetes. The glucagon-like peptide-1 (GLP-1) promoter, which is recognised by gut L-cells, is an appealing candidate for gene therapy purposes. The specific properties of L-cells suggest that L-cells and the GLP-1 promoter would be useful for diabetes therapy approaches. Results: In this study, L-cells were isolated from a primary intestinal cell line to create suitable target cells for insulin expression studies. The isolated cells displayed L-cell properties and were therefore used as an L-cell surrogate. Next, the isolated L-cells were transfected with the recombinant plasmid consisting of an insulin gene located downstream of the GLP-1 promoter. The secretion tests revealed that an increase in glucose concentration from 5 mM to 25 mM induced insulin gene expression in the L-cells by 2.7-fold. Furthermore, L-cells quickly responded to the glucose stimulation; the amount of insulin protein increased 2-fold in the first 30 minutes and then reached a plateau after 90 minutes. Conclusion: Our data showed that L-cells efficiently produced the mature insulin protein. In addition, the insulin protein secretion was positively regulated with glucose induction. In conclusion, GLP-1 promoter and L-cell could be potential candidates for diabetes gene therapy agents.
format Article
author Rasouli, Mina
Ahmad, Zalinah
Omar, Abdul Rahman
Allaudin, Zeenathul Nazariah
spellingShingle Rasouli, Mina
Ahmad, Zalinah
Omar, Abdul Rahman
Allaudin, Zeenathul Nazariah
Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
author_facet Rasouli, Mina
Ahmad, Zalinah
Omar, Abdul Rahman
Allaudin, Zeenathul Nazariah
author_sort Rasouli, Mina
title Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
title_short Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
title_full Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
title_fullStr Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
title_full_unstemmed Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
title_sort engineering an l-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment
publisher BioMed Central
publishDate 2011
url http://psasir.upm.edu.my/id/eprint/24523/1/24523.pdf
http://psasir.upm.edu.my/id/eprint/24523/
https://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-11-99
_version_ 1651869029706498048